Aurobindo Pharma Ltd
Fundamental Score
Aurobindo Pharma Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of AUROPHARMA across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Operating Margins (19.25%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 20.69 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (12.77x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹4214.84 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 41.81%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Risk Factors
2 factors identified
Weak Earnings Growth (4.05% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (3.87% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Financial Statements
Comprehensive financial data for Aurobindo Pharma Ltd
About AUROPHARMA
Business Overview
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Company Details
Key Leadership
Corporate Events
Latest News
AUROPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Aurobindo Pharma Ltd (AUROPHARMA)?
As of 21 Jan 2026, 08:44 am IST, Aurobindo Pharma Ltd (AUROPHARMA) is currently trading at ₹1121.00. The stock has a market capitalization of ₹70.80K (Cr).
Is AUROPHARMA share price Overvalued or Undervalued?
AUROPHARMA is currently trading at a P/E ratio of 20.69x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Aurobindo Pharma Ltd share price?
Key factors influencing AUROPHARMA's price include its quarterly earnings growth (Sales Growth: 6.28%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aurobindo Pharma Ltd a good stock for long-term investment?
Aurobindo Pharma Ltd shows a 5-year Profit Growth of 3.87% and an ROE of 11.08%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.22 before investing.
How does Aurobindo Pharma Ltd compare with its industry peers?
Aurobindo Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare AUROPHARMA's P/E of 20.69x and ROE of 11.08% against the industry averages to determine its competitive standing.
What is the P/E ratio of AUROPHARMA and what does it mean?
AUROPHARMA has a P/E ratio of 20.69x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹21 for every ₹1 of annual earnings.
How is AUROPHARMA performing according to Bull Run's analysis?
AUROPHARMA has a Bull Run fundamental score of 28.8/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does AUROPHARMA belong to?
AUROPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aurobindo Pharma Ltd.
What is Return on Equity (ROE) and why is it important for AUROPHARMA?
AUROPHARMA has an ROE of 11.08%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Aurobindo Pharma Ltd generates profits from shareholders' equity.
How is AUROPHARMA's debt-to-equity ratio and what does it indicate?
AUROPHARMA has a debt-to-equity ratio of 0.22, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is AUROPHARMA's dividend yield and is it a good dividend stock?
AUROPHARMA offers a dividend yield of 0.33%, which means you receive ₹0.33 annual dividend for every ₹100 invested.
How has AUROPHARMA grown over the past 5 years?
AUROPHARMA has achieved 5-year growth rates of: Sales Growth 6.55%, Profit Growth 3.87%, and EPS Growth 4.05%.
What is the promoter holding in AUROPHARMA and why does it matter?
Promoters hold 51.82% of AUROPHARMA shares, with 17.50% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is AUROPHARMA's market capitalization category?
AUROPHARMA has a market capitalization of ₹70799 crores, placing it in the Large-cap category.
How volatile is AUROPHARMA stock?
AUROPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for AUROPHARMA?
AUROPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is AUROPHARMA's operating profit margin trend?
AUROPHARMA has a 5-year average Operating Profit Margin (OPM) of 19.25%, indicating the company's operational efficiency.
How is AUROPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 6.28% and YoY Profit Growth of 3.80%.
What is the institutional holding pattern in AUROPHARMA?
AUROPHARMA has FII holding of 14.21% and DII holding of 27.60%. Significant institutional holding often suggests professional confidence in the stock.